I find The ASCO Post to be a good way to hear about new ideas that I might otherwise have missed. I read an article recently about the approval of nivolumab (Opdivo) for treating metastatic squamous non-small cell lung cancer (The ASCO Post, April 10, 2015). I thought it would have been much more useful if a reference to the published trial data or presentation was provided, but then learned that no such data had yet been published in a peer-reviewed journal or presented at a major oncology conference, like ASCO or ESMO (European Society of Medical Oncology). It is my hope that no oncologist would prescribe a new drug without seeing the published literature. ■

—Philip Champion MD, FRCPC

Charlottetown, PE, C1A 8T5, Canada